Skip to Main Content

An experimental drug from Stoke Therapeutics reduced the frequency of convulsive seizures in children with a rare form of epilepsy called Dravet syndrome, the company said Friday.

The study results are early and far from conclusive, but show the potential for a novel, RNA-based treatment to target the underlying genetic cause of the devastating childhood disorder, said Stoke CEO Ed Kaye.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment